Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Me...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/3/660 |
| _version_ | 1797488724374716416 |
|---|---|
| author | Bastien Collomb Amélie Dubromel Anne Gaëlle Caffin Chloé Herledan Virginie Larbre Amandine Baudouin Ariane Cerutti Laurence Couturier Magali Maire Lionel Karlin Delphine Maucort-Boulch Laure Huot Stéphane Dalle Emmanuel Bachy Hervé Ghesquieres Gilles Salles Sébastien Couraud Benoit You Gilles Freyer Véronique Trillet-Lenoir Florence Ranchon Catherine Rioufol |
| author_facet | Bastien Collomb Amélie Dubromel Anne Gaëlle Caffin Chloé Herledan Virginie Larbre Amandine Baudouin Ariane Cerutti Laurence Couturier Magali Maire Lionel Karlin Delphine Maucort-Boulch Laure Huot Stéphane Dalle Emmanuel Bachy Hervé Ghesquieres Gilles Salles Sébastien Couraud Benoit You Gilles Freyer Véronique Trillet-Lenoir Florence Ranchon Catherine Rioufol |
| author_sort | Bastien Collomb |
| collection | DOAJ |
| description | Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Methods Between September 2018 and May 2019, outpatients starting OAAs were included in a 12-week follow-up to assess 15 symptoms listed in the National Cancer Institute PRO Common Terminology Criteria for Adverse Events, using a 5-point scale of severity or frequency. Patients were requested to alert a referral nurse or pharmacist when they self-assessed high-level (level 3 or 4) symptoms. Results 407 questionnaires were completed by 63 patients in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms that were most commonly experienced were fatigue (>9 in 10 patients; 13.2% of symptoms declared), various psychological disorders (>9 in 10 patients; 28.6% of symptoms declared) and general pain (>8 in 10 patients; 9.4% of symptoms declared). Conclusion PROs are appropriate to detect potential adverse events in cancer outpatients treated by OAAs. This study is the first step for integrating the patient’s perspective in a digital e-health device in routine oncology care. |
| first_indexed | 2024-03-10T00:07:21Z |
| format | Article |
| id | doaj.art-92477568c5d94e4ab6aeab873c6d10e6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:07:21Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-92477568c5d94e4ab6aeab873c6d10e62023-11-23T16:06:35ZengMDPI AGCancers2072-66942022-01-0114366010.3390/cancers14030660Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral ProgramBastien Collomb0Amélie Dubromel1Anne Gaëlle Caffin2Chloé Herledan3Virginie Larbre4Amandine Baudouin5Ariane Cerutti6Laurence Couturier7Magali Maire8Lionel Karlin9Delphine Maucort-Boulch10Laure Huot11Stéphane Dalle12Emmanuel Bachy13Hervé Ghesquieres14Gilles Salles15Sébastien Couraud16Benoit You17Gilles Freyer18Véronique Trillet-Lenoir19Florence Ranchon20Catherine Rioufol21Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceDepartment of Hematology, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceDepartment of Statistics and Bioinformatics, Hospices Civils de Lyon, 69002 Lyon, FranceCellule Innovation, Département de la Recherche Clinique et de L’innovation, Hospices Civils de Lyon, 69002 Lyon, FranceDermatology Department, Groupement Hospitalier Lyon Sud, Hospices Civils de Lyon, 69495 Lyon, FranceDepartment of Hematology, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceDepartment of Hematology, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceDepartment of Hematology, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceCICLY Centre pour l’Innovation en Cancérologie de Lyon, Université Lyon 1-EA 3738, 69921 Lyon, FranceCICLY Centre pour l’Innovation en Cancérologie de Lyon, Université Lyon 1-EA 3738, 69921 Lyon, FranceCICLY Centre pour l’Innovation en Cancérologie de Lyon, Université Lyon 1-EA 3738, 69921 Lyon, FranceCICLY Centre pour l’Innovation en Cancérologie de Lyon, Université Lyon 1-EA 3738, 69921 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceUnité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Lyon, FranceBackground In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Methods Between September 2018 and May 2019, outpatients starting OAAs were included in a 12-week follow-up to assess 15 symptoms listed in the National Cancer Institute PRO Common Terminology Criteria for Adverse Events, using a 5-point scale of severity or frequency. Patients were requested to alert a referral nurse or pharmacist when they self-assessed high-level (level 3 or 4) symptoms. Results 407 questionnaires were completed by 63 patients in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms that were most commonly experienced were fatigue (>9 in 10 patients; 13.2% of symptoms declared), various psychological disorders (>9 in 10 patients; 28.6% of symptoms declared) and general pain (>8 in 10 patients; 9.4% of symptoms declared). Conclusion PROs are appropriate to detect potential adverse events in cancer outpatients treated by OAAs. This study is the first step for integrating the patient’s perspective in a digital e-health device in routine oncology care.https://www.mdpi.com/2072-6694/14/3/660patient reported outcomes (PROs)patient reported outcomes measures (PROMs)ambulatory careoral anticancer agent (OAA) |
| spellingShingle | Bastien Collomb Amélie Dubromel Anne Gaëlle Caffin Chloé Herledan Virginie Larbre Amandine Baudouin Ariane Cerutti Laurence Couturier Magali Maire Lionel Karlin Delphine Maucort-Boulch Laure Huot Stéphane Dalle Emmanuel Bachy Hervé Ghesquieres Gilles Salles Sébastien Couraud Benoit You Gilles Freyer Véronique Trillet-Lenoir Florence Ranchon Catherine Rioufol Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program Cancers patient reported outcomes (PROs) patient reported outcomes measures (PROMs) ambulatory care oral anticancer agent (OAA) |
| title | Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program |
| title_full | Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program |
| title_fullStr | Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program |
| title_full_unstemmed | Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program |
| title_short | Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program |
| title_sort | assessment of patient reported outcomes pros in outpatients taking oral anticancer drugs included in the real life oncoral program |
| topic | patient reported outcomes (PROs) patient reported outcomes measures (PROMs) ambulatory care oral anticancer agent (OAA) |
| url | https://www.mdpi.com/2072-6694/14/3/660 |
| work_keys_str_mv | AT bastiencollomb assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT ameliedubromel assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT annegaellecaffin assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT chloeherledan assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT virginielarbre assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT amandinebaudouin assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT arianecerutti assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT laurencecouturier assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT magalimaire assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT lionelkarlin assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT delphinemaucortboulch assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT laurehuot assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT stephanedalle assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT emmanuelbachy assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT herveghesquieres assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT gillessalles assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT sebastiencouraud assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT benoityou assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT gillesfreyer assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT veroniquetrilletlenoir assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT florenceranchon assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram AT catherinerioufol assessmentofpatientreportedoutcomesprosinoutpatientstakingoralanticancerdrugsincludedinthereallifeoncoralprogram |